- Home
- KLRS vs CEE Comparison
KLRS vs CEE Comparison
Compare KLRS & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | CEE |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 136.3M |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | KLRS | CEE |
|---|---|---|
| Price | $4.44 | $20.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 80.7K | 21.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $14.25 |
| 52 Week High | $11.88 | $21.98 |
Technical Indicators
Market Signals| Indicator | KLRS | CEE |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 47.89 |
| Support Level | $4.35 | $16.97 |
| Resistance Level | $5.43 | $21.86 |
| Average True Range (ATR) | 0.37 | 0.63 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 8.85 | 11.38 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.